{"description":"Subjects with either stable disease or objective response continued treatment until disease progression and/or intolerable toxicity at which patients were taken off study. Subjects were monitored for toxicity using NCI CTAE v3.0 Criteria. Dose adjustment was allowed per standard guidelines for zoledronic acid for decreased creatinine clearance. Patients who completed at least one treatment cycle were included in data analysis.","eventGroups":[{"deathsNumAffected":0,"deathsNumAtRisk":8,"description":"Zoledronic acid (Zometa) will be administered IV-4mg by infusion on Day 1 of a 3-week cycle followed by tumor assessment from CT and/or PET scans every 2 cycles.The treatment will take about 30-60 minutes with the infusion lasting about 15 minutes.This will continue until progression of disease and/or intolerable toxicity.","id":"EG000","otherNumAffected":0,"otherNumAtRisk":8,"seriousNumAffected":0,"seriousNumAtRisk":8,"title":"Zoledronic Acid (Zometa)"}],"frequencyThreshold":"0","timeFrame":"From baseline to 28 months"}